UY35065A - Fármaco combinado que comprende gemigliptina y metformina y método para su preparación - Google Patents

Fármaco combinado que comprende gemigliptina y metformina y método para su preparación

Info

Publication number
UY35065A
UY35065A UY0001035065A UY35065A UY35065A UY 35065 A UY35065 A UY 35065A UY 0001035065 A UY0001035065 A UY 0001035065A UY 35065 A UY35065 A UY 35065A UY 35065 A UY35065 A UY 35065A
Authority
UY
Uruguay
Prior art keywords
metformin
preparation
gemigliptin
combined drug
present
Prior art date
Application number
UY0001035065A
Other languages
English (en)
Inventor
Park Ki Sook
Kim Geun Tae
Yun Duck Il
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of UY35065A publication Critical patent/UY35065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención se refiere a un fármaco combinado que comprende gemigliptina y metformina como componentes activos, y a un método para su preparación. La composición farmacéutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina de acuerdo con la presente invención tiene un efecto superior en la prevención y el tratamiento de la diabetes y sus complejos trastornos, y reduce los efectos perjudiciales de cada componente. Además, la presente composición comprende gemigliptina y metformina en forma separada de modo de preservar las velocidades de disolución inherentes de ambos componentes y mejorar el cumplimiento por parte del paciente.
UY0001035065A 2012-10-08 2013-10-04 Fármaco combinado que comprende gemigliptina y metformina y método para su preparación UY35065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20120111404 2012-10-08

Publications (1)

Publication Number Publication Date
UY35065A true UY35065A (es) 2014-05-30

Family

ID=50477605

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035065A UY35065A (es) 2012-10-08 2013-10-04 Fármaco combinado que comprende gemigliptina y metformina y método para su preparación

Country Status (19)

Country Link
EP (1) EP2903602B1 (es)
KR (1) KR101526553B1 (es)
CN (2) CN104884051A (es)
AU (1) AU2013330679B2 (es)
BR (1) BR112015007360A8 (es)
CL (1) CL2015000857A1 (es)
DO (1) DOP2015000071A (es)
HK (1) HK1211849A1 (es)
MX (1) MX368184B (es)
MY (1) MY174238A (es)
PE (1) PE20150721A1 (es)
PH (1) PH12015500653B1 (es)
RU (1) RU2664422C2 (es)
SG (1) SG11201502241XA (es)
TW (1) TWI606848B (es)
UA (1) UA114527C2 (es)
UY (1) UY35065A (es)
WO (1) WO2014058188A1 (es)
ZA (1) ZA201501985B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102496851B1 (ko) 2015-04-10 2023-02-08 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법
MX2019005572A (es) * 2016-11-15 2019-08-14 Lg Chemical Ltd Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.
KR102372408B1 (ko) * 2018-10-31 2022-03-08 주식회사 엘지화학 제2형 당뇨병 치료용 약제학적 조성물
KR102633770B1 (ko) 2019-05-24 2024-02-02 주식회사 엘지화학 제2형 당뇨병 치료용 복합제제
CN112641776A (zh) * 2019-10-12 2021-04-13 江苏晶立信医药科技有限公司 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物
WO2022034944A1 (ko) * 2020-08-14 2022-02-17 주식회사 엘지화학 제2형 당뇨병 치료용 복합제제
CN112546013B (zh) * 2020-12-29 2022-06-10 平光制药股份有限公司 一种沙格列汀二甲双胍双层片及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003978A2 (en) * 2000-07-06 2002-01-17 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
NZ625577A (en) * 2009-10-02 2015-12-24 Boehringer Ingelheim Int Therapeutic uses of pharmaceutical compositions
EP2356985A1 (en) * 2010-02-10 2011-08-17 LEK Pharmaceuticals d.d. Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin
WO2012049566A1 (en) * 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
WO2012059416A1 (en) * 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2

Also Published As

Publication number Publication date
AU2013330679B2 (en) 2016-10-06
CL2015000857A1 (es) 2015-08-21
BR112015007360A8 (pt) 2018-08-14
CN110339176A (zh) 2019-10-18
BR112015007360A2 (pt) 2017-07-04
UA114527C2 (uk) 2017-06-26
RU2664422C2 (ru) 2018-08-17
PE20150721A1 (es) 2015-05-23
CN104884051A (zh) 2015-09-02
WO2014058188A1 (en) 2014-04-17
AU2013330679A1 (en) 2015-04-09
TW201416095A (zh) 2014-05-01
MX368184B (es) 2019-09-23
EP2903602A1 (en) 2015-08-12
PH12015500653A1 (en) 2015-05-11
KR101526553B1 (ko) 2015-06-09
EP2903602A4 (en) 2016-03-16
ZA201501985B (en) 2016-01-27
DOP2015000071A (es) 2018-06-30
PH12015500653B1 (en) 2015-05-11
MX2015004296A (es) 2015-08-07
AU2013330679A8 (en) 2015-04-16
RU2015117523A (ru) 2016-11-27
TWI606848B (zh) 2017-12-01
HK1211849A1 (en) 2016-06-03
KR20140045271A (ko) 2014-04-16
EP2903602B1 (en) 2019-09-18
MY174238A (en) 2020-04-01
SG11201502241XA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
BR112016013419A2 (pt) composições de liberação retardada de linaclotida
DOP2016000253A (es) Nuevos compuestos
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
CO2018004665A2 (es) Compuestos oxadiazoespíricos
CO6721030A2 (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartan y método para la preparación de la misma

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20220622